Cagrilintide
Cagrilintide is a long-acting amylin analogue, designed for the treatment of obesity. It works by promoting satiety and reducing food intake.
PEPTIDES LIST
- Adipotide (FTPP)
- AICAR
- AOD9604
- ARA-290
- B7-33
- BPC-157
- Bronchogen
- Cagrisema
- Cagrilintides
- Cardiogen
- Cartalax
- Cerebrolysin (215mg/ml, 10ml)
- Chonluten
- CJC-1295 DAC
- Cortagen
- DSIP
- Epithalon (Epitalon)
- Follistatin-315
- Follistatin-344
- FOXO4-DRI
- GHK-Cu (Copper Peptide)
- GHK Basic
- GHRP-2
- GHRP-6
- GHRH (GH-Releasing Hormone)
- Glutathione
- Gonadorelin (GnRH)
- GLP2 & GLP3
- hGH Fragment 176-191
- Hexarelin
- Humanin
- Ipamorelin
- Kisspeptin-10
- KPV (ACTH (11-13) alpha-MSH)
- Liraglutide (GLP-1 Analogue)
- Livagen
- LL-37 (CAP-18)
- Melanotan 2 (Melanotan II)
- Mezdutide
- MGF (C-terminal)
- ModGRF 1-29 (CJC-1295 No DAC)
- MK-677 (Ibutamoren)
- MOTS-c
- N-Acetyl Epithalon Amidate
- N-Acetyl Selank Amidate
- N-Acetyl Semax Amidate
- NAD+
- Ovagen
- Oxytocin+
- Pancragen
- PE-22-28
- PEG-MGF (Pegylated MGF)
- Pinealon
- PNC-27
- Prostamax
- PT-141 (Bremelanotide)
- P21 (P021)
- Retatrutide
- Snap8
- Tesa_Ipa_Blend
- Triblend
- Selank
- Semaglutide (GLP-1 Analogue)
- Semax
- Sermorelin
- SS-31
- Survodutide
- TB-500
- Tesamorelin
- Testagen
- Thymagen
- Thyrotropin-TRH
- Tirzepatide
- Triptorelin
- Vesugenas
- Vesilute
- Vilon
- VIP (Vasoactive Intestinal Peptide)
- GLP2
- GLP3
- Klow
- Klow8
- SLU-PP-332
- BAM-15
- Orforglipron
- Noopept
- 9-Me-BC
- Methylene Blue
- Lemon Bottle
Cagrilintide is a cutting-edge peptide that has garnered significant attention for its potential applications in managing metabolic disorders, particularly obesity and type 2 diabetes. This peptide is part of a growing class of therapeutic agents designed to target specific metabolic pathways with high precision, offering a promising alternative to conventional treatments.
Cagrilintide's therapeutic potential is primarily due to its ability to regulate appetite and promote weight loss. By mimicking natural hormones in the body, Cagrilintide can effectively reduce hunger, increase satiety, and consequently help in managing body weight and improving metabolic health.
Cagrilintide is described as a modified version of amylin (a hormone that works with insulin to help regulate blood sugar). In research discussions, it’s explored for obesity/type 2 diabetes support and broader metabolic/cardiovascular interest.
Dosing (per dose): 0.6 mg – 4.5 mg
Route & Frequency: Once weekly is listed.
Titration: Increase by 0.6 mg every 4 weeks until the goal response is achieved.
Note: More is not always better.
| Weeks | Weekly Dose | Notes |
|---|---|---|
| Weeks 1–4 | 0.6 mg | Starting dose |
| Weeks 5–8 | 1.2 mg | +0.6 mg after 4 weeks |
| Weeks 9–12 | 1.8 mg | +0.6 mg after another 4 weeks |
| Extended use (optional) | Continue +0.6 mg every 4 weeks | Do not exceed 4.5 mg per dose |
Cycling:
• 3-month cycles, with a minimum 1 month off
• Cycles may be extended depending on response and goal
Caution & Contraindications:
Caution: Use caution in individuals with hypoglycemia (low blood sugar), pancreatic conditions, kidney conditions, and/or gastrointestinal conditions.
• May cause nausea, diarrhea, and stomach discomfort.
Contraindications:
• Individuals with type 1 diabetes and/or severe kidney impairment
• Pregnant individuals
Reconstitution Options (Vial Formats):
• 5 mg
• 10 mg
Reconstitution (General Handling):
• Use sterile technique and follow the product’s label/spec sheet for diluent type and volume.
• Add diluent slowly along the vial wall; gently swirl/roll until dissolved (avoid vigorous shaking).
• Store according to label guidance; refrigerate if applicable and protect from light.
Sequence: A chain of amino acids with a specific sequence designed to mimic the hormone amylin.
Molecular Formula: C152H252N44O42 (example formula)
Molecular Weight: 2611.41 grams per mole (example weight)
Preclinical Studies
Preclinical studies on Cagrilintide have shown promising results, with significant reductions in body weight and improvements in metabolic parameters observed in animal models. These studies have provided valuable insights into the peptide's mechanisms of action and its potential benefits in treating metabolic disorders.
Clinical Trials
Cagrilintide is currently undergoing clinical trials to evaluate its safety and efficacy in humans. Early results from these trials have been encouraging, demonstrating the peptide's ability to promote weight loss and improve glycemic control in patients with obesity and type 2 diabetes. These findings support the potential of Cagrilintide as a novel therapeutic option for managing these conditions.
The future of Cagrilintide in metabolic health is promising. As research continues to validate its efficacy and safety, Cagrilintide is expected to become a key player in the treatment of obesity and type 2 diabetes. Its ability to precisely target metabolic pathways offers a new approach to managing these conditions, potentially leading to better patient outcomes.
Cagrilintide's development represents a significant advancement in peptide-based therapies. Its unique mechanism of action and therapeutic benefits highlight the potential of peptides in addressing complex metabolic disorders. Continued research and development in this field could lead to the discovery of new peptides with similar or enhanced therapeutic properties.
The ultimate goal of Cagrilintide's development is to improve the quality of life for individuals struggling with obesity and type 2 diabetes. By offering a targeted and effective treatment option, Cagrilintide has the potential to help patients achieve better health outcomes, reduce the burden of chronic diseases, and enhance overall well-being.
The red data points show the impact of different doses of Cagrilintide on weight loss. The graph highlights the significant weight loss observed with Cagrilintide treatment, demonstrating its efficacy.
Graph B shows the effect of Cagrilintide treatment on BMI compared to the control group. The blue line represents the BMI of the control group, and the red line represents the BMI of individuals who received Cagrilintide treatment. The sharp drop in BMI in the treatment group underscores the potential of Cagrilintide in managing weight and related health issues.
Article Author :
The above literature was researched, edited and organized by Dr. Logan, M.D. Dr. Logan holds a doctorate degree from https://case.edu/medicine/Case Western Reserve University School of Medicine and a B.S. in molecular biology.
Case Western Reserve University School of Medicine
ALL ARTICLES AND PRODUCT INFORMATION PROVIDED ON THIS WEBSITE ARE FOR INFORMATIONAL AND EDUCATIONAL PURPOSES ONLY.
The product information featured on this website pertains exclusively to in-vitro studies. In-vitro studies, also known as ‘in glass’ studies, are conducted outside of living organisms. It’s important to emphasize that these products do not constitute medicines or drugs and have not received FDA approval for the prevention, treatment, or cure of any medical conditions, ailments, or diseases. It is crucial to note that the introduction of these products into the bodies of humans or animals is strictly prohibited by law.
THIS PRODUCT IS INTENDED AS A RESEARCH CHEMICAL ONLY. This designation allows the use of research chemicals strictly for in vitro testing and laboratory experimentation only. All product information available on this website is for educational purposes only. Bodily introduction of any kind into humans or animals is strictly forbidden by law. This product should only be handled by licensed, qualified professionals. This product is not a drug, food, or cosmetic and may not be misbranded, misused or mislabled as a drug, food or cosmetic.
